AG
AMAM

Artal Group’s Ambrx Biopharma Inc AMAM Stock Holding History

Artal Group’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-702,291
Closed -$11.6M – 126
2023
Q2 		$11.6M Hold
702,291
– – 0.37% 43
2023
Q1 		$6.26M Sell
702,291
-1,450,000
-67% -$7.29M 0.37% 56
2022
Q4 		$4.89M Hold
2,152,291
– – 0.28% 64
2022
Q3 		$2.32M Hold
2,152,291
– – 0.12% 86
2022
Q2 		$5.7M Hold
2,152,291
– – 0.32% 52
2022
Q1 		$8.87M Hold
2,152,291
– – 0.37% 53
2021
Q4 		$19.4M Buy
2,152,291
+1,302,291
+153% +$14.5M 0.57% 48
2021
Q3 		$11.5M Hold
850,000
– – 0.28% 73
2021
Q2 		$16.7M Buy
+850,000
New +$14.5M 0.38% 64

Other funds holding AMAM

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.98B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return